Evaluation of beta-cell sensitivity to glucose and first-phase insulin secretion in obese dogs

American Journal of Veterinary Research

Volumn 72, Issue 3, 2011, Pages 357-366

  Verkest, Kurt R ^a   Fleeman, Linda M ^a,b   Rand, Jacquie S ^a   Morton, John M ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Animal Diabetes Australia   (Australia)

^c Jemora Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN;

ANIMAL MODEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROVOCATION TEST;

ANIMALS; BLOOD GLUCOSE; DOG DISEASES; DOGS; GLUCAGON; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; OBESITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 79953099675     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.72.3.357     Document Type: Article

References (47)

1. Bergman RN, Kim SP, Catalano KJ, et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006;14(suppl):16S-19S.
2. Rand JS, Fleeman LM, Farrow HA, et al. Canine and feline diabetes mellitus: nature or nurture? J Nutr 2004;134(suppl):2072S-2080S.
3. Polonsky KS. Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes 1999;107(suppl):s124-s127. (Pubitemid 29457104)
4. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002;19:527-534. (Pubitemid 35300672)
5. Appleton DJ, Rand JS, Sunvold GD. Insulin sensitivity decreases with obesity, and lean cats with low insulin sensitivity are at greatest risk of glucose intolerance with weight gain. J Feline Med Surg 2001;3:211-228.
6. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002;51(suppl):S117-S122.
7. Cavaghan MK. The beta cell and first-phase insulin secretion. Medscape Diabetes Endocrinol [serial online] 2004;6. Available at: www.medscape.org/ viewarticle/483307. Accessed July 30, 2004.
8. Cherrington AD, Sindelar D, Edgerton D, et al. Physiological consequences of phasic insulin release in the normal animal. Diabetes 2002;51(suppl 1):S103-S108. (Pubitemid 34761503)
9. Getty L, Hamilton-Wessler M, Ader M, et al. Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile. Diabetes 1998;47:1941-1947. (Pubitemid 28549203)
10. Gredal C, Rosenfalck AM, Dejgaard A, et al. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes. Scand J Clin Lab Invest 2007;67:327-336. (Pubitemid 46643381)
11. Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care 1990;13:992-1010. (Pubitemid 20260737)
12. Toffolo G, Bergman RN, Finegood DT, et al. Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes 1980;29:979-990. (Pubitemid 11017924)
13. Larson BT, Lawler DF, Spitznagel EL Jr, et al. Improved glucose tolerance with lifetime diet restriction favorably affects disease and survival in dogs. J Nutr 2003;133:2887-2892. (Pubitemid 37099777)
14. Mattheeuws D, Rottiers R, Baeyens D, et al. Glucose tolerance and insulin response in obese dogs. J Am Anim Hosp Assoc 1984;20:287-293.
15. van Citters GW, Kabir M, Kim SP, et al. Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding. J Clin Endocrinol Metab 2002;87:5191-5198.
16. Bailhache E, Ouguerram K, Gayet C, et al. An insulin-resistant hypertriglyceridaemic normotensive obese dog model: assessment of insulin resistance by the euglycaemic hyperinsulinaemic clamp in combination with the stable isotope technique. J Anim Physiol Anim Nutr (Berl) 2003;87:86-95. (Pubitemid 36452987)
17. Kaiyala KJ, Prigeon RL, Kahn SE, et al. Reduced beta-cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding. Am J Physiol 1999;277:E659-E667. (Pubitemid 29522618)
18. Eigenmann JE, Eigenmann RY, Rijnberk A, et al. Progesterone-controlled growth hormone overproduction and naturally occurring canine diabetes and acromegaly. Acta Endocrinol (Copenh) 1983;104:167-176. (Pubitemid 13000593)
19. Yoneda H, Ikegami H, Yamamoto Y, et al. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care 1992;15:1517-1521.
20. Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991;40:166-180.
21. Montgomery TM, Nelson RW, Feldman EC, et al. Basal and glucagon- stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism. J Vet Intern Med 1996;10:116-122. (Pubitemid 126700942)
22. LaFlamme D. Development and validation of a body condition score system for dogs. Canine Pract 1997;22(4):10-15.
23. Fleeman L, Rand J. Efficacy of intermittent low-dose heparinised saline flushes for maintaining indwelling peripheral and central intravenous catheters in diabetic dogs. Aust Vet Pract 2001;31:126-134. (Pubitemid 33659762)
24. Marshall RD, Rand JS, Morton JM. Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. J Vet Pharmacol Ther 2008;31:205-212. (Pubitemid 351677390)
25. Rowland M, Tozer TN. Assessment of AUC. In: Clinical pharmacokinetics: concepts and applications. Baltimore: Williams & Wilkins, 1995;469-472.
26. Link KR, Rand JS. Reference values for glucose tolerance and glucose tolerance status in cats. J Am Vet Med Assoc 1998;213:492-496. (Pubitemid 128473015)
27. Stata longitudinal/panel-data reference manual. 10th ed. College Station, Tex: Stata Press, 2007.
28. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ 1996;312:1079. (Pubitemid 26125136)
29. Hoenig M, Alexander S, Holson J, et al. Influence of glucose dosage on interpretation of intravenous glucose tolerance tests in lean and obese cats. J Vet Intern Med 2002;16:529-532. (Pubitemid 135747430)
30. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev 2008;29:351-366. (Pubitemid 351679704)
31. Imamura T, Koffler M, Helderman JH, et al. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. Diabetes 1988;37:600-609.
32. Zini E, Osto M, Franchini M, et al. Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat. Diabetologia 2009;52:336-346.
33. Donath MY, Storling J, Berchtold LA, et al. Cytokines and β-cell biology: from concept to clinical translation. Endocr Rev 2008;29:334-350. (Pubitemid 351679703)
34. Haataja L, Gurlo T, Huang CJ, et al. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008;29:303-316. (Pubitemid 351679701)
35. Scheuner D, Kaufman RJ. The unfolded protein response: a pathway that links insulin demand with β-cell failure and diabetes. Endocr Rev 2008;29:317-333. (Pubitemid 351679702)
36. Cotton RB, Cornelius LM, Theran P. Diabetes mellitus in the dog: a clinicopathologic study. J Am Vet Med Assoc 1971;159:863-870.
37. Dixon J, Sanford J. Pathological features of spontaneous canine diabetes mellitus. J Comp Pathol 1962;72:153-166.
38. Watson PJ, Roulois AJA, Scase T, et al. Prevalence and breed distribution of chronic pancreatitis at post-mortem examination in first-opinion dogs. J Small Anim Pract 2007;48:609-618. (Pubitemid 350050354)
39. Gilead S, Gazit E. The role of the 14-20 domain of the islet amyloid polypeptide in amyloid formation. Exp Diabetes Res 2008;2008:256954.
40. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 1997;94:4637-4641. (Pubitemid 27194295)
41. Shimabukuro M, Wang MY, Zhou YT, et al. Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A 1998;95:9558-9561. (Pubitemid 28506270)
42. Kharroubi I, Rasschaert J, Eizirik DL, et al. Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun 2003;312:1118-1122. (Pubitemid 37490931)
43. Byrne MM, Sturis J, Sobel RJ, et al. Elevated plasma glucose 2 h postchallenge predicts defects in β-cell function. Am J Physiol Endocrinol Metab 1996;270:E572-E579.
44. Friedenberg R, Metz R, Mako M, et al. Differential plasma insulin response to glucose and glucagon stimulation following ethanol priming. Diabetes 1971;20:397-403.
45. Zangeneh F, Arora PS, Dyck PJ, et al. Effects of duration of type 2 diabetes mellitus on insulin secretion. Endocr Pract 2006;12:388-393. (Pubitemid 44717597)
46. Scheen AJ, Castillo MJ, Lefebvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 1996;22:397-406. (Pubitemid 26401312)
47. Rottiers R, Mattheeuws D, Kaneko JJ, et al. Glucose uptake and insulin secretory responses to intravenous glucose loads in the dog. Am J Vet Res 1981;42:155-158.